2022 World Conference on Lung Cancer (ePosters)-EP08.02-006. Data from Real World to Evaluate the Efficacy of Almonertinib in EGFR-mutant NSCLC Patients

Pdf Summary

A study was conducted to evaluate the efficacy and safety of almonertinib in the treatment of EGFR-mutant non-small cell lung cancer (NSCLC) patients in a real-world setting. The study included 100 patients who were treated with almonertinib at the Henan Cancer Hospital in China from April 2020 to March 2021. The progression-free survival (PFS), objective response rate (ORR), disease control rate (DCR), and overall survival (OS) were analyzed, along with prognostic factors and safety.<br /><br />The results showed that among the 100 patients, 71% were female, 54% were less than 60 years old, and 19% had a history of smoking. 55% had EGFR 19Del mutation, and 41% had EGFR L858R mutation. The ORR for patients who received almonertinib as first-line treatment was 71%, with a median PFS of 16.7 months and OS not yet reached. Among patients who received almonertinib after progression on prior EGFR-TKI therapy, the ORR for T790M-positive patients was 50.0%, with a median PFS of 11.9 months and OS not yet reached. The ORR for T790M-negative patients was 25.6%, with a median PFS of 12.1 months and OS not yet reached.<br /><br />No significant difference in efficacy was observed between T790M-positive and T790M-negative patients. The efficacy of almonertinib was also comparable in patients with brain or meningeal metastasis and those without. The study identified elevated creatine kinase as a significant predictive factor for longer PFS.<br /><br />In conclusion, almonertinib showed good efficacy and safety in treating EGFR-mutant NSCLC patients. It was effective regardless of the presence of brain metastases or T790M mutation after prior EGFR-TKI progression. Elevated creatine kinase levels were found to be a predictor for longer PFS. Further studies are needed to validate these findings.

Asset Subtitle

Huijuan Wang

Meta Tag

Speaker Huijuan Wang

Topic Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments

Keywords

almonertinib

EGFR-mutant non-small cell lung cancer

real-world setting

progression-free survival

objective response rate

disease control rate

overall survival

T790M-positive

T790M-negative

elevated creatine kinase